Published on: Tuesday, June 4, 2024

Groundbreaking Weight Loss Drug Wegovy Reduces Risk of Heart Attack and Stroke

A Game-Changer for Heart Disease Prevention

In a groundbreaking development, the popular weight loss drug Wegovy has been approved by the FDA to reduce the risk of serious heart problems, including heart attacks, strokes, and heart disease-related deaths. This marks a significant milestone, as Wegovy becomes the first weight loss medication to offer such cardiovascular benefits.

Remarkable Clinical Trial Results

The approval comes after a major clinical trial involving individuals with cardiovascular disease or risk factors. The study found that weekly injections of Wegovy (semaglutide) reduced the risk of heart attack, stroke, or heart disease-related death by an impressive 20% compared to placebo.

Addressing a Leading Cause of Death

This breakthrough could have far-reaching implications in the fight against heart disease, which remains the leading cause of death worldwide. By combining weight loss and cardiovascular benefits, Wegovy offers a powerful tool for individuals struggling with obesity and related health risks.

A Promising Future for Weight Loss Drugs

The success of Wegovy in reducing heart attack and stroke risk has opened new avenues for weight loss drugs. Researchers are optimistic that this development could pave the way for more comprehensive treatments that address both obesity and its associated cardiovascular complications.

A Holistic Approach to Health

While Wegovy represents a significant advancement, experts emphasize the importance of a holistic approach to health. A balanced diet, regular exercise, and lifestyle modifications remain crucial components of any effective strategy for weight loss and heart disease prevention.

Find out more about 'Groundbreaking Weight Loss Drug Wegovy Reduces Risk of Heart Attack and Stroke'

Obesity drug slashes risk of heart attack or stroke 'regardless of ...

Anti-obesity jabs could reduce the risk of heart attacks, strokes or heart failure in obese people irrespective of the amount of weight they lose while ...

Weight loss jab could reduce heart attack risk, study finds

Obesity jabs could cut the risk of heart attacks and strokes in people even if they fail to lose much weight, according to an analysis of a study funded by ...

FDA Approves First Treatment to Reduce Risk of Serious Heart Problems ...

The FDA approved a new use for a drug to reduce the risk of cardiovascular disease, heart attack and stroke in ... “Wegovy is now the first weight loss medication to also be approved to help ...

Wegovy approved to lessen heart attack, stroke risk in overweight ...

This image provided by Novo Nordisk in January 2023 shows packaging for the company's Wegovy medication. The popular weight-loss drug can now be used to reduce the risk of stroke, heart attacks ...

Weight-loss drug Wegovy cuts risk of stroke, heart attacks, company said

The popular obesity drug Wegovy cuts the risk of cardiovascular events, such as heart attack and stroke, by 20%, drugmaker Novo Nordisk said Tuesday. The findings are the first to demonstrate that ...

Wegovy study: Semaglutide reduced risks for heart attacks ... - UCHealth

The blockbuster new weight loss drugs, Wegovy and Ozempic, could become even more popular now that researchers have found that injections of semaglutide — the drug in Wegovy and Ozempic — sharply cut heart attacks, strokes and cardiac deaths in addition to helping people lose a significant percentage of weight. New information related to the weight loss drugs is emerging as research ...

FDA Approves Wegovy Weight Loss Drug to Reduce Heart Attack Risk

Novo Nordisk’s weight loss drug Wegovy received the go-ahead from the Food and Drug Administration to list heart-related benefits on its label, the first in its class with this expanded offering.

Wegovy shown to reduce risk of heart attack, stroke in major ... - CNN

The weight loss drug Wegovy was shown to reduce the risk of heart attack, stroke, or heart disease-related death by 20% in a major clinical trial in people with cardiovascular disease, the first ...

Popular weight-loss drug Wegovy now approved for heart disease. Here's ...

By comparison, a 2023 trial of another new heart drug, bempedoic acid, found a 13% reduction in risk of heart attacks and strokes over three years. Wegovy may join the ranks of other effective ...

Weight Loss Drug Wegovy Approved by FDA to Prevent Heart Attacks and ...

Wegovy (semaglutide) is the first weight loss medication approved for the prevention of heart attack, stroke, and heart disease–related death in adults who are overweight or have obesity. The 0. ...

The weight loss drug Wegovy reduces serious heart disease - Vox

Health. The weight loss drug Wegovy reduces serious heart disease. A clinical trial suggests the drug could help people avoid the world’s leading cause of death. by Keren Landman, MD. Aug 9 ...

The weight-loss drug Wegovy lowered heart attack risk in a large trial

The weight-loss drug Wegovy lowered heart attack risk in a large trial. Weekly injections of the medication cut the number of serious heart problems. Results from a new clinical trial suggest that ...